<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
-------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) September 7, 2000
PROTEIN DESIGN LABS, INC.
(Exact name of registrant as specified in its charter)
-------------------------
<TABLE>
<CAPTION>
--------------------------------------------------------------------------------------------------
<S> <C> <C>
Delaware 0-19756 94-3023969
----------------------------------- ------------------------ ---------------------------------
(State or other jurisdiction of (Commission File Number) (IRS Employer Identification No.)
incorporation)
--------------------------------------------------------------------------------------------------
</TABLE>
34801 Campus Drive
Fremont View, California 94555
(Address of principal executive offices) (Zip Code)
--------------------------------------------------------------------------------
Registrant's telephone number, including area code (510) 574-1400
(Former name or former address, if changed since last report)
<PAGE> 2
ITEM 5. OTHER MATTERS
On September 7, 2000, Protein Design Labs, Inc. (the "Company") issued a
press release announcing that the Company has agreed to adapt for human use a
murine antibody from Eli Lilly and Company ("Lilly").
On September 18, 2000, the Company issued a press release announcing that
the Company has entered into a second antibody humanization agreement with
Lilly.
On September 25, 2000, the Company issued a press release announcing the
Company's public offering of 3,000,000 shares of its common stock at a price of
$118.4375 per share.
On September 29, 2000, the Company issued a press release announcing the
completion of the Company's public offering of 3,000,000 shares of its common
stock at a price of $118.4375 per share.
The foregoing matters are discussed in greater detail in the Company's
press releases, copies of which are attached hereto as Exhibits 99.1, 99.2, 99.3
and 99.4, respectively.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits:
<TABLE>
<S> <C>
99.1 Press Release dated September 7, 2000.
99.2 Press Release dated September 18, 2000.
99.3 Press Release dated September 25, 2000.
99.4 Press Release dated September 29, 2000.
</TABLE>
<PAGE> 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
PROTEIN DESIGN LABS, INC.
Date: October 6, 2000 By: /s/ Douglas O. Ebersole
-----------------------------------------
Douglas O. Ebersole
Senior Vice President,
Legal and Licensing
<PAGE> 4
EXHIBIT INDEX
<TABLE>
<CAPTION>
Exhibit No. Description
<S> <C>
99.1 Press Release dated September 7, 2000.
99.2 Press Release dated September 18, 2000.
99.3 Press Release dated September 25, 2000.
99.4 Press Release dated September 29, 2000.
</TABLE>
